These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25923941)

  • 1. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Ergelen R; Akyuz U; Aydin Y; Eren F; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):667-71. PubMed ID: 25923941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Aykut UE; Akyuz U; Yesil A; Eren F; Gerin F; Ergelen R; Celikel CA; Yilmaz Y
    Scand J Gastroenterol; 2014 Nov; 49(11):1343-8. PubMed ID: 25259621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Dincses E; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1149-53. PubMed ID: 26049712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis.
    Rosso C; Caviglia GP; Abate ML; Vanni E; Mezzabotta L; Touscoz GA; Olivero A; Marengo A; Rizzetto M; Bugianesi E; Smedile A
    Dig Liver Dis; 2016 Jan; 48(1):55-61. PubMed ID: 26514735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience.
    Lee CK; Perez-Atayde AR; Mitchell PD; Raza R; Afdhal NH; Jonas MM
    J Pediatr; 2013 Oct; 163(4):1058-64.e2. PubMed ID: 23759423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease.
    Cengiz M; Ozenirler S
    Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1293-9. PubMed ID: 26302023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Subasi CF; Aykut UE; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):137-41. PubMed ID: 25486027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease.
    Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N
    J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis.
    Rath T; Roderfeld M; Güler C; Wenzel C; Graf J; Beitinger F; Roeb E; Zachoval R
    Scand J Gastroenterol; 2011 Nov; 46(11):1369-80. PubMed ID: 21905976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease.
    Mahadeva S; Mahfudz AS; Vijayanathan A; Goh KL; Kulenthran A; Cheah PL
    J Dig Dis; 2013 Nov; 14(11):604-10. PubMed ID: 23859493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
    Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M
    Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients.
    Fernandes FF; Ferraz ML; Andrade LE; Dellavance A; Terra C; Pereira G; Pereira JL; Campos F; Figueiredo F; Perez RM
    J Clin Gastroenterol; 2015 Mar; 49(3):235-41. PubMed ID: 24714186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease.
    Alkhouri N; Sedki E; Alisi A; Lopez R; Pinzani M; Feldstein AE; Nobili V
    Liver Int; 2013 Jan; 33(1):79-85. PubMed ID: 23146095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.
    Lebensztejn DM; Wierzbicka A; Socha P; Pronicki M; Skiba E; Werpachowska I; Kaczmarski M
    Acta Biochim Pol; 2011; 58(4):563-6. PubMed ID: 22140659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
    Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
    Younossi ZM; Page S; Rafiq N; Birerdinc A; Stepanova M; Hossain N; Afendy A; Younoszai Z; Goodman Z; Baranova A
    Obes Surg; 2011 Apr; 21(4):431-9. PubMed ID: 20532833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.